Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation
Published: 04 March 2021
In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.
Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.
- Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
- Interpret safety and cardiovascular data from RCTs in the context of real-world experience
- Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
- Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC
- Interventional Cardiologists
More from this programme
When to Initiate a NOAC and Patient Suitability (data presentation)
Overview of Safety and Cardiovascular Data
Dealing with Complications:
Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)
NOAC Use with Ablation and Intervention
Senior Consultant in Electrophysiology and Devices
Professor Jan Steffel is a Cardiologist and Senior Consultant in Electrophysiology and Devices at the Hirslanden Clinic in Zurich and Professor of Cardiology at the University of Zurich.
He has over 150 publications in international and national journals and is board-certified in Internal Medicine and Cardiology. He was Associate Editor for the European Heart Journal from 2012 and became Deputy Editor in 2017. He is a member of the Foederatio Medicorum Helveticorum (FMH), Swiss Society for General Internal Medicine (SGAIM), Swiss Society for Cardiology (SGK) and European Society of Cardiology (ESC).